▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1938 by analyst upside · 2026-09-29
RYTM
Rhythm Pharmaceuticals, Inc.
Healthcare · Market Cap $7B · P/E 0x
ANALYST PRICE TARGET
+40.6%
implied upside to consensus target
Current Price $98.56
Consensus Target $138.59
Bull Target $160.0
Bear Target $105.0
Analysts Covering 17
ANALYST CONSENSUS - BUY
Strong Buy
5
Buy
10
Hold
2
Sell
0
52-Week Low $74.5
52-Week High $122.2
YTD Return -6.1%
FUNDAMENTALS
Market Cap $7B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-3.12
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $240M
Profit Margin -85.6%
52-WEEK RANGE
52-Week Low $74.5
52-Week High $122.2
Current Price $98.56
Bear Target $105.0
Bull Target $160.0
● Now $98.56 ● Target $138.59
TRADING DATA
Avg Volume 654K
YTD Return -6.1%
Analyst Count 17
Consensus Buy
Upside to Target +40.6%
Last Updated 2026-09-29

ANALYST SUMMARY

Rhythm Pharmaceuticals, Inc. (RYTM) is currently trading at $98.56 with a Wall Street consensus price target of $138.59, implying potential upside of 40.6% over the next 12 months. 17 analysts currently cover RYTM, with a consensus rating of Buy - 88% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $160.0, while the most cautious has a target of $105.0.

RYTM operates in the Healthcare sector with a market capitalisation of $7B. The stock is down 6.1% year-to-date and is currently trading near the upper end of its 52-week range of $74.5 – $122.2.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for RYTM, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Deutsche Bank ● Initiated
Hold 2026-08-28 Building track record
JP Morgan - Reiterated
Overweight → Overweight 2026-08-07 43% win rate (7 calls)
Citigroup - Reiterated
Buy → Buy 2026-08-05 Building track record
RBC Capital - Reiterated
Outperform → Outperform 2026-08-05 Building track record
Citizens - Reiterated
Market Outperform → Market Outperform 2026-08-05 Building track record
JP Morgan ● Initiated
Overweight 2026-07-27 43% win rate (7 calls)
RBC Capital - Reiterated
Outperform → Outperform 2026-07-07 Building track record
Canaccord Genuity - Reiterated
Buy → Buy 2026-06-16 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
63
out of 100
Coverage depth
22/30
Consensus clarity
19/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →